BACKGROUND: The prognosis of HCC remains poor mainly because of the lack of diagnosis biomarkers especially in patients with cirrhosis background. METHODS: To identify serum biomarkers for HCC, we use cleavable stable isotope labeling (cICAT) combined with LC-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) to compare the serum proteome between liver cirrhosis and HCC patients. Sera from nine liver cirrhosis patients and nine HCC patients were selected for screening study. Then the alpha-1-acid glycoprotein (AGP) was chosen for validation by western blot. AGP was measured in the separate validation study including 52 HCC patients and 40 liver cirrhosis patients by rate nephelometry. Its value for HCC diagnosis from liver cirrhosis was also appreciated through receiver operating curve (ROC). RESULTS: We quantified and identified 31 different proteins which include AGP, complement C4, haptoglobin, alpha-1-antitrypsin precursor, alpha-2-macroglobulin precursor, prothrombin precursor and ubiquitin carboxyl-terminal hydrolase 44 (USP44), etc. The serum concentration of AGP in HCC patients (n = 52) was significantly higher than in liver cirrhosis (n = 40) (P < 0.005) in validation study. AGP was useful for discrimination of the HCC cases from LC patients when the AFP levels were below 500 ng/ml. The area under curve (AUC) of the AGP and the combination of AGP and AFP were 0.834 (P < 0.0005, 95% CI: 0.734-0.934) and 0.880 (P < 0.0005, 95% CI, 0.789-0.970) separately, which are higher than AFP alone (0.538, P = 0.604, 95% CI: 0.386-0.689). CONCLUSION: cICAT combined with LC-MS/MS-based serum proteome analysis can be useful in the screening of serum biomarkers for HCC. Alpha-1-acid glycoprotein combining AFP could aid the diagnosis of HCC.
BACKGROUND: The prognosis of HCC remains poor mainly because of the lack of diagnosis biomarkers especially in patients with cirrhosis background. METHODS: To identify serum biomarkers for HCC, we use cleavable stable isotope labeling (cICAT) combined with LC-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) to compare the serum proteome between liver cirrhosis and HCC patients. Sera from nine liver cirrhosispatients and nine HCC patients were selected for screening study. Then the alpha-1-acid glycoprotein (AGP) was chosen for validation by western blot. AGP was measured in the separate validation study including 52 HCC patients and 40 liver cirrhosispatients by rate nephelometry. Its value for HCC diagnosis from liver cirrhosis was also appreciated through receiver operating curve (ROC). RESULTS: We quantified and identified 31 different proteins which include AGP, complement C4, haptoglobin, alpha-1-antitrypsin precursor, alpha-2-macroglobulin precursor, prothrombin precursor and ubiquitin carboxyl-terminal hydrolase 44 (USP44), etc. The serum concentration of AGP in HCC patients (n = 52) was significantly higher than in liver cirrhosis (n = 40) (P < 0.005) in validation study. AGP was useful for discrimination of the HCC cases from LC patients when the AFP levels were below 500 ng/ml. The area under curve (AUC) of the AGP and the combination of AGP and AFP were 0.834 (P < 0.0005, 95% CI: 0.734-0.934) and 0.880 (P < 0.0005, 95% CI, 0.789-0.970) separately, which are higher than AFP alone (0.538, P = 0.604, 95% CI: 0.386-0.689). CONCLUSION: cICAT combined with LC-MS/MS-based serum proteome analysis can be useful in the screening of serum biomarkers for HCC. Alpha-1-acid glycoprotein combining AFP could aid the diagnosis of HCC.
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: Philip L Ross; Yulin N Huang; Jason N Marchese; Brian Williamson; Kenneth Parker; Stephen Hattan; Nikita Khainovski; Sasi Pillai; Subhakar Dey; Scott Daniels; Subhasish Purkayastha; Peter Juhasz; Stephen Martin; Michael Bartlet-Jones; Feng He; Allan Jacobson; Darryl J Pappin Journal: Mol Cell Proteomics Date: 2004-09-22 Impact factor: 5.911
Authors: Eun Young Song; Kyoung A. Kim; Yung Dai Kim; Eun Young Lee; Hong Soo Lee; Hee Jung Kim; Byung Min Ahn; Yong Kyung Choe; Cheorl Ho Kim; Tai Wha Chung Journal: Hepatol Res Date: 2003-08 Impact factor: 4.288
Authors: Laura F Steel; Donna Shumpert; Michael Trotter; Steven H Seeholzer; Alison A Evans; W Thomas London; Raymond Dwek; Timothy M Block Journal: Proteomics Date: 2003-05 Impact factor: 3.984
Authors: Frank Stegmeier; Michael Rape; Viji M Draviam; Grzegorz Nalepa; Mathew E Sowa; Xiaolu L Ang; E Robert McDonald; Mamie Z Li; Gregory J Hannon; Peter K Sorger; Marc W Kirschner; J Wade Harper; Stephen J Elledge Journal: Nature Date: 2007-04-19 Impact factor: 49.962
Authors: Dominik A Megger; Thilo Bracht; Michael Kohl; Maike Ahrens; Wael Naboulsi; Frank Weber; Andreas-Claudius Hoffmann; Christian Stephan; Katja Kuhlmann; Martin Eisenacher; Jörg F Schlaak; Hideo A Baba; Helmut E Meyer; Barbara Sitek Journal: Mol Cell Proteomics Date: 2013-03-05 Impact factor: 5.911
Authors: Indra Bachtiar; Valentine Kheng; Gunawan A Wibowo; Rino A Gani; Irsan Hasan; Andri Sanityoso; Unggul Budhihusodo; Syafruddin Ar Lelosutan; Ruswhandi Martamala; Wenny A Achwan; Soewignyo Soemoharjo; Ali Sulaiman; Laurentius A Lesmana; Susan Tai Journal: BMC Res Notes Date: 2010-11-23
Authors: Gustavo Ferrín; Manuel Rodríguez-Perálvarez; Patricia Aguilar-Melero; Isidora Ranchal; Camilo Llamoza; Clara I Linares; Sandra González-Rubio; Jordi Muntané; Javier Briceño; Pedro López-Cillero; José Luis Montero-Álvarez; Manuel de la Mata Journal: PLoS One Date: 2015-03-19 Impact factor: 3.240
Authors: Haddy K S Fye; Cynthia Wright-Drakesmith; Holger B Kramer; Suzi Camey; Andre Nogueira da Costa; Adam Jeng; Alasana Bah; Gregory D Kirk; Mohamed I F Sharif; Nimzing G Ladep; Edith Okeke; Pierre Hainaut; Simon D Taylor-Robinson; Benedikt M Kessler; Maimuna E Mendy Journal: PLoS One Date: 2013-07-30 Impact factor: 3.240